Bobillo, Sabela
Joffe, Erel http://orcid.org/0000-0002-7883-289X
Sermer, David
Mondello, Patrizia http://orcid.org/0000-0002-0355-3757
Ghione, Paola
Caron, Philip C.
Hamilton, Audrey
Hamlin, Paul A.
Horwitz, Steven M.
Kumar, Anita
Matasar, Matthew J.
Batlevi, Connie L. http://orcid.org/0000-0002-9036-9463
Moskowitz, Alison
Noy, Ariela http://orcid.org/0000-0002-3001-4898
Owens, Collette N.
Palomba, M. Lia http://orcid.org/0000-0001-5099-9156
Straus, David
von Keudell, Gottfried
Dogan, Ahmet http://orcid.org/0000-0001-6576-5256
Zelenetz, Andrew D.
Seshan, Venkatraman E. http://orcid.org/0000-0002-9258-2698
Younes, Anas http://orcid.org/0000-0002-0001-4133
Funding for this research was provided by:
Fundación Alfonso Martín Escudero
Article History
Received: 7 January 2021
Revised: 29 April 2021
Accepted: 10 May 2021
First Online: 16 June 2021
Competing interests
: AD has received personal fees from Roche, Corvus Pharmaceuticals, Physicians’ Education Resource, Seattle Genetics, Peerview Institute, Oncology Specialty Group, Pharmacyclics, Celgene, Novartis, Takeda and research grants from National Cancer Institute and Roche. CLB has received grant funding from Janssen, Novartis, Epizyme, Xynomics, Bayer, BMS, and served as a consultant for Life Sci, GLG, Celgene, Seattle Genetics, Xynomics, and holds honorarium from Dava Oncology. PH receives research support from Portola, Novartis/GSK, Molecular Templates, Janssen Pharmaceuticals, and served as consultant for Karyopharm, Juno, Portola, Celgene, AstraZeneca. SH has received research funding from ADCT therapeutics, Aileron, Forty-Seven, Verastem, Kyowa Hakko Kirin, Millennium Pharmaceuticals Inc, Celgene, Trillium, Daiichii Sankyo, and consults for Astex, Affimed, Merck Sharp and Dome, Kyowa Hakko Kirin Pharma, Corvus Pharmaceuticals Inc, Celgene, Portola Pharmaceuticals, Takeda Millennium, Innate Pharma, Verastem, Miragen Therapeutics Inc, Seattle Genetics, ADCT. AK receives research funding from Abbvie Pharmaceuticals, Adaptive Biotechnologies, Pharmacyclics, Seattle Genetics, and serves on advisory board for Celgene and AstraZeneca. MLP receives honoraria from Flagship Ventures, Novartis, Evelo, Seres Therapeutics, Jazz Pharmaceuticals, Therakos, Amgen, Merk and consults for Merk and Pharmacyclics. AN receives honoraria from Janssen, Pharmacyclics, Prime Oncology, and consults for Medscape, and serves on advisory board for Janssen, and serves on the speakers’ bureau for Prime Oncology, and receives research funding for Rafael Pharma and Pharmacyclics. AM receives research support from Seattle Genetics, Merck, Bristol-Myers Squibb, Incyte, and receives honorarium from Kyowa Hakko Kirin Pharma, Miragen Therapeutics, Takeda Pharmaceuticals, ADC Therapeutics, Seattle Genetics, Cell Medica, Bristol-Myers Squibb, Erytech Pharma. DS consults for InPractice Elselvier, Seattle Genetics, and is on speaker’s bureau for Medical Crossfire. ADZ consults for Genentech/Roche, Gilead, Celgene, Janssen, Amgen, Novartis, Adaptive Biotechnology, Verastem, and serves on advisory board for MorphoSys, Gilead, Genentech, Abbvie, AstraZeneca, Pharmacyclics, and receives research funding from MEI Pharmaceuticals, Roche, Gilead, Beigene. AY received research support from Janssen, Curis, Merck, BMS, Syndax, Roche, and honorarium from Janssen, Abbvie, Merck, Curis, Epizyme, Roche, Takeda, and consulted for Biopath, Xynomics, Epizyme, Roche, Celgene, HCM. AY is currently an employee of AstraZeneca. The remaining authors declare no competing interests.